4(5)-(2-bromoethyl)imidazole hydrobromide | 30290-07-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4(5)-(2-bromoethyl)imidazole hydrobromide
• 英文别名: 4-(2-bromoethyl)imidazole hydrobromide；4-bromoethylimidazole hydrobromide；4(5)-[2-(bromo)ethyl]imidazole hydrobromide；4-(2-bromoethyl)-1H-imidazole hydrobromide；5-(2-Bromoethyl)-1H-imidazole hydrobromide；5-(2-bromoethyl)-1H-imidazole;hydrobromide
• CAS: 30290-07-4
• 化学式: BrH*C₅H₇BrN₂
• 分子量: 255.94
• InChiKey: KIZBIKPGZVSGOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.92
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  28.7
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4(5)-(2-bromoethyl)imidazole hydrobromide 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 17.0h， 生成 2-<4-imidazolyl>ethylhydrazine dihydrochloride
  参考文献：
  名称：

  Bieganski; Ganellin; Kusche, European Journal of Medicinal Chemistry, 1985, vol. 20, # 5, p. 433 - 437

  摘要：

  DOI：

文献信息

• Bicyclic inhibitors of protein farnesyl transferase
  申请人：Warner-Lambert Company

  公开号：US06133303A1

  公开（公告）日：2000-10-17

  The present invention provides compounds of Formula (I). The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula (I). ##STR1##

  本发明提供了化合物的结构式(I)。本发明还提供了一种治疗癌症、治疗或预防再狭窄或动脉粥样硬化的方法。本发明还提供了含有结构式(I)化合物的药学上可接受的组合物。
• Altman, Janina; Wilchek, Meir, Journal of Heterocyclic Chemistry, 1988, vol. 25, p. 915 - 916
  作者：Altman, Janina、Wilchek, Meir

  DOI：——

  日期：——
• Cardiotonic agents. 6. Histamine analogs as potential cardiovascular selective H2 agonists
  作者：John W. Lampe、Reda G. Hanna、Thomas A. Piscitelli、Yuo Ling Chou、Paul W. Erhardt、William C. Lumma、Stanley S. Greenberg、William R. Ingebretsen、Dennis C. Marshall、Jay Wiggins

  DOI：10.1021/jm00168a024

  日期：1990.6

  Twenty-six alkyl and aralkyl histamine analogues were prepared as potential cardiotonic agents. Compounds were designed to allow interaction with a putative secondary aryl binding site at the H2 receptor, the presence of which was inferred from the structure of cyprohepatadine, which is known to have H2-antagonist properties. The compounds were examined for inotropic activity in ferret papillary muscle. Potent inotropic activity was generally found in N-alkyl- and N,N-dialkylimidazole-4-ethanamines, whereas N-(amidoalkyl)imidazole-4-ethanamines and N-alkylimidazole-4-propanamines were at best weakly active. Five compounds were examined in screens designed to assess hemodynamic effects and gastric acid secretion in vivo. Two of these compounds, alpha-(3-phenyl-2-transpropenyl)-1H-imidazole-4-ethanamine and N-heptyl-1H-imidazole-4-ethanamine, showed positive inotropic activity with minimal effects on heart rate and mean arterial pressure in vivo; however, both compounds were found to stimulate gastric acid secretion. These results demonstrate that selectivity between various H2-receptor-mediated activities can be obtained with substituted histamine analogues.
• Reversible Inhibitors of the Gastric (H+/K+)-ATPase. 4. Identification of an Inhibitor with an Intermediate Duration of Action
  作者：Colin A. Leach、Thomas H. Brown、Robert J. Ife、David J. Keeling、Michael E. Parsons、Colin J. Theobald、Kenneth J. Wiggall

  DOI：10.1021/jm00014a026

  日期：1995.7

  3-Acyl-4-(arylamino)quinolines were previously identified as gastric (H+/K+)-ATPase inhibitors, and clinical efficacy has been demonstrated for compound 3 (SK&F 96067). In the present study the further structure-activity relationship of this series is developed. Only a limited range of substituents are tolerated on the N-aryl ring or the 6- and 7-positions of the quinoline, and although hydroxylated derivatives were identified possessing markedly greater affinity for the enzyme, none of these proved to have adequate potency after oral dosing. In contrast, the 8-position of the quinoline ring proved suitable for a wide variety of substituents, allowing modification of physicochemical properties while retaining primary activity. This led to the identification of compound 4 (SK&F 97574), which combines good oral potency with a somewhat longer duration of action than 3 (though much shorter than covalent inhibitors such as omeprazole). This compound was selected for further development and evaluation in man.
• Isothiourea analogues of histamine as potent agonists or antagonists of the histamine H3-receptor
  作者：H van der Goot、MJP Schepers、GJ Sterk、H Timmerman

  DOI：10.1016/0223-5234(92)90185-4

  日期：1992.8

  The synthesis and H-3-activity of a series of isothiourea analogues of histamine have been described. It has been shown that S-[2-(4(5)-imidazolyl)ethylisothiourea (VUF 8325) is a potent H-3-agonist measured as the electrically evoked contraction of the guinea-pig ileum. Upon methylation of the imidazole system or the isothiourea moiety a decrease in affinity was observed leading to either weak agonists or weak antagonists. Introduction of N-(phenylalkyl) substituents at the isothiourea part gives rise to highly potent H-3-antagonists. Particularly the 4-chlorobenzyl group appeared to be favourable in the series described resulting in a histamine H-3-antagonist with a pA2-value of 9.9.